Resveratrol inhibits prostate cancer growth and hormone resistance:An in vivo study
SHAO Hongchao
LUO Qiyuan
GAO Wenbin
LUO Wen
YE Mushi
Abstract:Objective To investigate the inhibitory effects of resveratrol(Res)on the growth of hormone-dependent and castration-resistant prostate cancer(PCa)and explore its mechanisms.Methods Subcutaneous xenograft models were established in nude mice using the human prostate cancer cell lines LNCaP(hormone-sensitive)and its castration-resistant derivative LNCaP-B.Thirty nude mice were randomly divided into three groups:control group,Res-treated and docetaxel.Tumor growth was recorded.Quantitative real-time polymerase chain reaction(qRT-PCR)and Western blot were performed to assess androgen receptor(AR)mRNA and protein expression levels in tumor tissues.Results Moderate-and high-dose Res significantly inhibited the growth of both LNCaP and LNCaP-B xenografts in a dose-dependent manner,with statistical significance(P<0.05).qRT-PCR and Western blot analyses revealed that Res markedly downregulated AR mRNA expression and protein levels compared to the control group.However,no significant pathological alterations were observed in HE-stained tumor sections.Conclusions Resveratrol suppresses the growth of hormone-dependent and castration-resistant prostate cancer by inhibiting AR expression and signaling pathway activity.These findings highlight its potential as an adju-vant therapeutic agent to androgen deprivation therapy(ADT),providing a theoretical foundation for its clinical application in PCa treatment.
Keywords:resveratrolprostate cancernudemiceLNCaP cellsLNCaP-B cells
Publication Date:2025-06-25
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:5( 1835-1839 )
The Journal of Practical Medicine

The Journal of Practical Medicine

ISTICPKU
ISSN:1006-5725
Year, Vol.(Issue):2025,41(12)